Connect with us

International

5 Top Biotech Companies by Market Cap

What are the biggest names in biotechnology? We count down the five top biotech stocks based on market cap.
The post 5 Top Biotech Companies by Market Cap appeared first on Investing News Network.

Published

on

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can and does insulate investors from volatility.

 

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Top biotech companies to consider

So if you’re feeling skittish, take heart: You’re not without options — these top biotech companies below may be good bets. This list was compiled using Investing.com’s stock screener and companies are listed in order of market cap size. All numbers were current as of June 9, 2021.

1. Johnson & Johnson (NYSE:JNJ)

Market capitalization: US$430.32 billion

Starting off this list of the top biotech companies is Johnson & Johnson, a holding company focused on the overarching life science field. Life science companies often specify their focus, but thanks to its massive scale, Johnson & Johnson covers many areas through its subsidiaries.

Johnson & Johnson’s treatment focus is on six therapeutic areas: cardiovascular disease and metabolism, infectious diseases and vaccines, neuroscience, oncology, immunology and pulmonary hypertension. The company’s pharmaceutical pipeline includes 14 novel drug launches expected by the end of 2023. The most notable drug coming down the pike is focused on multiple myeloma; it is a CAR-T therapy called cilta-cel and is a joint venture with Legend Biotech (NASDAQ:LEGN).

Johnson & Johnson-owned Janssen Pharmaceuticals is the maker of one of the big four COVID-19 vaccines on the market. The single-shot vaccine received emergency use authorization from the US Food and Drug Administration (FDA) in late February 2021. While the Janssen vaccine is considered 66 percent effective in preventing coronavirus infections, reported incidences of rare but potentially fatal blood clots led to the FDA halting its use until more research could be conducted.

In late April 2021, the FDA and the Centers for Disease Control gave approval for Janssen vaccine use to resume. Johnson & Johnson plans to file for a biologics license application with the FDA later in 2021.

2. Pfizer (NYSE:PFE)

Market capitalization: US$217.41 billion

New York-based multinational biopharmaceutical company Pfizer is one of the most recognized names in medicine around the world. For more than 150 years, the firm has developed a global portfolio of medicines and vaccines, including many of the world’s best-known consumer healthcare products.

Like Johnson & Johnson, Pfizer also charged headfirst into the fray in the fight against COVID-19. The company and its partner BioNTech (NASDAQ:BNTX) have developed what has become the most sought after of the coronavirus vaccines for both its safety and efficacy.

In June 2021, the FDA granted approval for another Pfizer-developed vaccine, this time for a conjugate vaccine known as PREVNAR 20 that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia.

3. Eli Lilly and Company (NYSE:LLY)

Market capitalization: US$211.66 billion

Founded in 1876 and headquartered in Indianapolis, Eli Lilly and Company develops products for human and animal health. The company’s human pharmaceutical products include therapies for endocrinology, neuroscience, oncology, immunology and cardiovascular disorders.

Eli Lilly has research and development facilities and manufacturing plans in eight countries and has done clinical research in over 50 countries.

  Life Science and Healthcare Investing in 2020 report cover

Coronavirus:An Overview for Investors

 
COVID-19 continues to impact world markets. Get INN’s overview of coronavirus investing.
 

The pharma giant has signed some large deals with biotech partners this year. In January 2021, Eli Lilly inked a US$300 million seed funding agreement with San Diego-based biotech firm Blacksmith Medicines. The agreement includes a research collaboration between the two companies and is aimed at advancing human metalloenzyme targets.

In May 2021, Eli Lily signed a US$1.5 billion deal with London biotech firm MiNA Therapeutics to develop several novel drug candidates using MiNA’s proprietary RNA technology platform.

4. AbbVie (NYSE:ABBV)

Market capitalization: US$198.38 billion

This biopharmaceutical company is one of the most well-known organizations in the industry. AbbVie’s operations are spread throughout 75 countries and its products are sold in over 170 nations. The Chicago-based company aims to treat a range of diseases in five key areas.

The company’s treatment areas include: virology, which includes hepatitis C and HIV; neurodegenerative diseases, such as schizophrenia, Alzheimer’s disease, Parkinson’s disease and multiple sclerosis; immunology, including spondyloarthropathies, hidradenitis suppurativa and uveitis; oncology, which is the treatment of cancer; and general medicine, which includes women’s health.

In May 2020, AbbVie completed its acquisition of Allergan in a staggering US$63 billion blockbuster deal. In May 2021, AbbVie received European Commission approval for ENCLYXTO in combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.

The following month, Health Canada granted approval for the company’s RINVOQ, an oral, once daily, selective and reversible JAK inhibitor for adults with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying anti-rheumatic drugs.

5. Novo Nordisk (NYSE:NVO)

Market capitalization: US$186.34 billion

Founded in 1923 and headquartered in Denmark, Novo Nordisk is most focused on diabetes and other serious chronic diseases such as cardiovascular diseases, obesity and rare blood and endocrine disorders. The company’s operations span 80 countries and it markets products in around 170 countries.

Novo Nordisk acquired Corvidia Therapeutics for US$2.1 billion in 2020, adding ziltivekimab, an antibody under development for reducing the risk of major adverse cardiovascular events in patients with chronic kidney disease and atherosclerotic cardiovascular disease. Further adding to its cardiovascular pipeline, the company signed a deal in May 2021 with Japanese biotech company Heartseed to develop an investigational cell therapy that uses purified cardiomyocytes derived from induced pluripotent stem cells for the treatment of heart failure caused by ischaemic heart disease.

Novo Nordisk also has a clinical collaboration with Gilead Sciences (NASDAQ:GILD) to study the safety and efficacy of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, and a fixed-dose combination of Gilead’s investigational FXR agonist cilofexor and investigational ACC inhibitor firsocostat, both alone and in combination in people with compensated cirrhosis due non-alcoholic steatohepatitis.

This is an updated version of an article originally published by the Investing News Network in 2016.

Don’t forget to follow us @INN_LifeScience for real-time news updates!

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

 

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

The post 5 Top Biotech Companies by Market Cap appeared first on Investing News Network.

Read More

Continue Reading

International

There will soon be one million seats on this popular Amtrak route

“More people are taking the train than ever before,” says Amtrak’s Executive Vice President.

Published

on

While the size of the United States makes it hard for it to compete with the inter-city train access available in places like Japan and many European countries, Amtrak trains are a very popular transportation option in certain pockets of the country — so much so that the country’s national railway company is expanding its Northeast Corridor by more than one million seats.

Related: This is what it's like to take a 19-hour train from New York to Chicago

Running from Boston all the way south to Washington, D.C., the route is one of the most popular as it passes through the most densely populated part of the country and serves as a commuter train for those who need to go between East Coast cities such as New York and Philadelphia for business.

Veronika Bondarenko captured this photo of New York’s Moynihan Train Hall. 

Veronika Bondarenko

Amtrak launches new routes, promises travelers ‘additional travel options’

Earlier this month, Amtrak announced that it was adding four additional Northeastern routes to its schedule — two more routes between New York’s Penn Station and Union Station in Washington, D.C. on the weekend, a new early-morning weekday route between New York and Philadelphia’s William H. Gray III 30th Street Station and a weekend route between Philadelphia and Boston’s South Station.

More Travel:

According to Amtrak, these additions will increase Northeast Corridor’s service by 20% on the weekdays and 10% on the weekends for a total of one million additional seats when counted by how many will ride the corridor over the year.

“More people are taking the train than ever before and we’re proud to offer our customers additional travel options when they ride with us on the Northeast Regional,” Amtrak Executive Vice President and Chief Commercial Officer Eliot Hamlisch said in a statement on the new routes. “The Northeast Regional gets you where you want to go comfortably, conveniently and sustainably as you breeze past traffic on I-95 for a more enjoyable travel experience.”

Here are some of the other Amtrak changes you can expect to see

Amtrak also said that, in the 2023 financial year, the Northeast Corridor had nearly 9.2 million riders — 8% more than it had pre-pandemic and a 29% increase from 2022. The higher demand, particularly during both off-peak hours and the time when many business travelers use to get to work, is pushing Amtrak to invest into this corridor in particular.

To reach more customers, Amtrak has also made several changes to both its routes and pricing system. In the fall of 2023, it introduced a type of new “Night Owl Fare” — if traveling during very late or very early hours, one can go between cities like New York and Philadelphia or Philadelphia and Washington. D.C. for $5 to $15.

As travel on the same routes during peak hours can reach as much as $300, this was a deliberate move to reach those who have the flexibility of time and might have otherwise preferred more affordable methods of transportation such as the bus. After seeing strong uptake, Amtrak added this type of fare to more Boston routes.

The largest distances, such as the ones between Boston and New York or New York and Washington, are available at the lowest rate for $20.

Read More

Continue Reading

International

The next pandemic? It’s already here for Earth’s wildlife

Bird flu is decimating species already threatened by climate change and habitat loss.

I am a conservation biologist who studies emerging infectious diseases. When people ask me what I think the next pandemic will be I often say that we are in the midst of one – it’s just afflicting a great many species more than ours.

I am referring to the highly pathogenic strain of avian influenza H5N1 (HPAI H5N1), otherwise known as bird flu, which has killed millions of birds and unknown numbers of mammals, particularly during the past three years.

This is the strain that emerged in domestic geese in China in 1997 and quickly jumped to humans in south-east Asia with a mortality rate of around 40-50%. My research group encountered the virus when it killed a mammal, an endangered Owston’s palm civet, in a captive breeding programme in Cuc Phuong National Park Vietnam in 2005.

How these animals caught bird flu was never confirmed. Their diet is mainly earthworms, so they had not been infected by eating diseased poultry like many captive tigers in the region.

This discovery prompted us to collate all confirmed reports of fatal infection with bird flu to assess just how broad a threat to wildlife this virus might pose.

This is how a newly discovered virus in Chinese poultry came to threaten so much of the world’s biodiversity.

H5N1 originated on a Chinese poultry farm in 1997. ChameleonsEye/Shutterstock

The first signs

Until December 2005, most confirmed infections had been found in a few zoos and rescue centres in Thailand and Cambodia. Our analysis in 2006 showed that nearly half (48%) of all the different groups of birds (known to taxonomists as “orders”) contained a species in which a fatal infection of bird flu had been reported. These 13 orders comprised 84% of all bird species.

We reasoned 20 years ago that the strains of H5N1 circulating were probably highly pathogenic to all bird orders. We also showed that the list of confirmed infected species included those that were globally threatened and that important habitats, such as Vietnam’s Mekong delta, lay close to reported poultry outbreaks.

Mammals known to be susceptible to bird flu during the early 2000s included primates, rodents, pigs and rabbits. Large carnivores such as Bengal tigers and clouded leopards were reported to have been killed, as well as domestic cats.

Our 2006 paper showed the ease with which this virus crossed species barriers and suggested it might one day produce a pandemic-scale threat to global biodiversity.

Unfortunately, our warnings were correct.

A roving sickness

Two decades on, bird flu is killing species from the high Arctic to mainland Antarctica.

In the past couple of years, bird flu has spread rapidly across Europe and infiltrated North and South America, killing millions of poultry and a variety of bird and mammal species. A recent paper found that 26 countries have reported at least 48 mammal species that have died from the virus since 2020, when the latest increase in reported infections started.

Not even the ocean is safe. Since 2020, 13 species of aquatic mammal have succumbed, including American sea lions, porpoises and dolphins, often dying in their thousands in South America. A wide range of scavenging and predatory mammals that live on land are now also confirmed to be susceptible, including mountain lions, lynx, brown, black and polar bears.

The UK alone has lost over 75% of its great skuas and seen a 25% decline in northern gannets. Recent declines in sandwich terns (35%) and common terns (42%) were also largely driven by the virus.

Scientists haven’t managed to completely sequence the virus in all affected species. Research and continuous surveillance could tell us how adaptable it ultimately becomes, and whether it can jump to even more species. We know it can already infect humans – one or more genetic mutations may make it more infectious.

At the crossroads

Between January 1 2003 and December 21 2023, 882 cases of human infection with the H5N1 virus were reported from 23 countries, of which 461 (52%) were fatal.

Of these fatal cases, more than half were in Vietnam, China, Cambodia and Laos. Poultry-to-human infections were first recorded in Cambodia in December 2003. Intermittent cases were reported until 2014, followed by a gap until 2023, yielding 41 deaths from 64 cases. The subtype of H5N1 virus responsible has been detected in poultry in Cambodia since 2014. In the early 2000s, the H5N1 virus circulating had a high human mortality rate, so it is worrying that we are now starting to see people dying after contact with poultry again.

It’s not just H5 subtypes of bird flu that concern humans. The H10N1 virus was originally isolated from wild birds in South Korea, but has also been reported in samples from China and Mongolia.

Recent research found that these particular virus subtypes may be able to jump to humans after they were found to be pathogenic in laboratory mice and ferrets. The first person who was confirmed to be infected with H10N5 died in China on January 27 2024, but this patient was also suffering from seasonal flu (H3N2). They had been exposed to live poultry which also tested positive for H10N5.

Species already threatened with extinction are among those which have died due to bird flu in the past three years. The first deaths from the virus in mainland Antarctica have just been confirmed in skuas, highlighting a looming threat to penguin colonies whose eggs and chicks skuas prey on. Humboldt penguins have already been killed by the virus in Chile.

A colony of king penguins.
Remote penguin colonies are already threatened by climate change. AndreAnita/Shutterstock

How can we stem this tsunami of H5N1 and other avian influenzas? Completely overhaul poultry production on a global scale. Make farms self-sufficient in rearing eggs and chicks instead of exporting them internationally. The trend towards megafarms containing over a million birds must be stopped in its tracks.

To prevent the worst outcomes for this virus, we must revisit its primary source: the incubator of intensive poultry farms.

Diana Bell does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Read More

Continue Reading

International

This is the biggest money mistake you’re making during travel

A retail expert talks of some common money mistakes travelers make on their trips.

Published

on

Travel is expensive. Despite the explosion of travel demand in the two years since the world opened up from the pandemic, survey after survey shows that financial reasons are the biggest factor keeping some from taking their desired trips.

Airfare, accommodation as well as food and entertainment during the trip have all outpaced inflation over the last four years.

Related: This is why we're still spending an insane amount of money on travel

But while there are multiple tricks and “travel hacks” for finding cheaper plane tickets and accommodation, the biggest financial mistake that leads to blown travel budgets is much smaller and more insidious.

A traveler watches a plane takeoff at an airport gate.

Jeshoots on Unsplash

This is what you should (and shouldn’t) spend your money on while abroad

“When it comes to traveling, it's hard to resist buying items so you can have a piece of that memory at home,” Kristen Gall, a retail expert who heads the financial planning section at points-back platform Rakuten, told Travel + Leisure in an interview. “However, it's important to remember that you don't need every souvenir that catches your eye.”

More Travel:

According to Gall, souvenirs not only have a tendency to add up in price but also weight which can in turn require one to pay for extra weight or even another suitcase at the airport — over the last two months, airlines like Delta  (DAL) , American Airlines  (AAL)  and JetBlue Airways  (JBLU)  have all followed each other in increasing baggage prices to in some cases as much as $60 for a first bag and $100 for a second one.

While such extras may not seem like a lot compared to the thousands one might have spent on the hotel and ticket, they all have what is sometimes known as a “coffee” or “takeout effect” in which small expenses can lead one to overspend by a large amount.

‘Save up for one special thing rather than a bunch of trinkets…’

“When traveling abroad, I recommend only purchasing items that you can't get back at home, or that are small enough to not impact your luggage weight,” Gall said. “If you’re set on bringing home a souvenir, save up for one special thing, rather than wasting your money on a bunch of trinkets you may not think twice about once you return home.”

Along with the immediate costs, there is also the risk of purchasing things that go to waste when returning home from an international vacation. Alcohol is subject to airlines’ liquid rules while certain types of foods, particularly meat and other animal products, can be confiscated by customs. 

While one incident of losing an expensive bottle of liquor or cheese brought back from a country like France will often make travelers forever careful, those who travel internationally less frequently will often be unaware of specific rules and be forced to part with something they spent money on at the airport.

“It's important to keep in mind that you're going to have to travel back with everything you purchased,” Gall continued. “[…] Be careful when buying food or wine, as it may not make it through customs. Foods like chocolate are typically fine, but items like meat and produce are likely prohibited to come back into the country.

Related: Veteran fund manager picks favorite stocks for 2024

Read More

Continue Reading

Trending